Prokidney News

News

Ticker

PROK

ISIN

US74291D1046

Revenue Net Income P/E P/S EBIT Dividend Directors Dealings Stocks Market capitalization Debt Liabilities Equity AAQS Employees ROE ROA ROCE News Documents

Prokidney Eulerpool News

Prokidney Stock News

Prokidney is being monitored by journalists and investors worldwide. We gather the latest Prokidney news here.

January 31·
SeekingAlpha
ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably
January 14·
SeekingAlpha
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
January 14·
SeekingAlpha
ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
December 27·
Yahoo
ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright
December 16·
Benzinga
This MYR Group Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday
November 23·
Yahoo
While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership
November 10·
Benzinga
ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate
October 29·
Yahoo
ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference
September 19·
SeekingAlpha
ProKidney: Slow-Burning 'Buy' Opportunity Based On 2027 Approval Of Kidney Disease Therapy
September 8·
SeekingAlpha
ProKidney Corp. (PROK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
September 3·
SeekingAlpha
ProKidney Corp. (PROK) Presents At Citi's Biopharma Back To School Conference Transcript
August 12·
Yahoo
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
August 12·
Benzinga
ProKidney Q2 EPS $(0.13) Beats $(0.15) Estimate, Sales $221.000K
July 22·
Yahoo
ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement
July 22·
Yahoo
Meet the Biotech Stock That Rocketed 775% Higher
July 20·
Yahoo
JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)
July 17·
Yahoo
PROKIDNEY CP (PROK) Upgraded to Strong Buy: What Does It Mean for the Stock?
July 17·
Yahoo
Best Momentum Stocks to Buy for July 17th
July 17·
Yahoo
New Strong Buy Stocks for July 17th
July 15·
Benzinga
UBS Maintains Buy on ProKidney, Raises Price Target to $8

Prokidney Stock Press Releases

Prokidney regularly publishes news on the company's website that are relevant for investors.

Prokidney News 2026

This page contains all current news, analysis and press releases for Prokidney stock (PROK, ISIN: US74291D1046). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Prokidney.

Prokidney Stock

Prokidney Prokidney Corp, based in Winston-Salem, North Carolina, is a clinical-stage biotechnology company focused on developing cell therapy platforms for chronic kidney diseases. The company employs 231 people and is listed on the stock market since June 30, 2021. Its lead product, Renal Autologous Cell Therapy (REACT), uses a patient's own kidney cells to preserve kidney function in chronic kidney disease patients. REACT is currently in global Phase 3 trials and multiple Phase 2 trials for diabetic kidney disease.